Emerging therapeutic angles via sEV modulation. Pharmacological inhibition of neutral sphingomyelinase 2 (nSMase2) has been shown to significantly reduce neuronal exosome secretion and decrease interstitial levels of amyloid-β (Aβ) and phosphorylated tau in 5xFAD AD mouse models. This evidence concerns the gene SMPD3 and Alzheimer disease.